ArticleFrontiers in oncology2025
Case Report: A long-term survival case of primary malignant melanoma of the lung with meningeal metastasis.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Malignant melanoma originating in the lungs is relatively rare, accounting for only 0.01% of lung tumors, and has a poor prognosis and is prone to distant metastasis. Notably, melanoma is the third most common source of intracranial metastases in adults, after lung and breast cancer. Primary malignant melanoma of the lung with meningeal metastasis is more rare and has a worse prognosis. There is no effective and unified treatment plan in clinical practice, and the main treatment is comprehensive treatment, which mainly includes surgery, radiation therapy, immunotherapy and targeted therapy. Case presentation: The patient was a 52-year-old male with no history of smoking. PET-CT showed a mass in the main bronchus of the right lung, consistent with the metabolic changes of malignant melanoma. Combined with pathology, we finally identified the patient as a primary pulmonary malignant melanoma. About two years later, the patient developed meningeal metastases. The patients was mainly treated with radiation therapy combined with immunotherapy, and the overall survival was about 30 months. Conclusions: The diagnosis of pulmonary primary malignant melanoma requires a combination of many factors and is easy to be misdiagnosed. At present, there is no specific effective treatment plan, and such patients have a poor prognosis, are prone to distant metastasis, and their survival will be greatly shortened. The survival period of the patient in this case is longer than the average survival period of such patients, and the possibility of benefiting from immunotherapy is higher. Radiotherapy also reduces the discomfort symptoms of the patient to a certain extent, prolongs the survival of the patient, and provides certain ideas for clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.